GLSI

Greenwich Lifesciences Inc

Add to Watchlist

Advanced Chart

11.480

+0.02(0.175%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

11.910

Open

11.560

VWAP

11.51

Vol

25.75K

Mkt Cap

156.48M

Low

11.3521

Amount

296.27K

EV/EBITDA(TTM)

Total Shares

12.88M

153.08M

EV/OCF(TTM)

P/S(TTM)

Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9-amino acid transmembrane peptide of the human epidermal growth factor receptor 2 (HER2) /neu protein, a cell surface receptor protein that is expressed in a variety of common cancers. It has commenced a Phase III clinical trial, Flamingo-01, an immunotherapy to prevent breast cancer recurrences. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to induce GP2 peptide-specific immunity. GP2 treatment is administered via an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. Its cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells while not affecting normal cells or to deliver immune system components to inhibit the spread of cancer.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

-0.360

+80%

-0.340

-44.26%

-0.350

+40%

Estimates Revision

The market is revising No Change the revenue expectations for Greenwich LifeSciences, Inc. (GLSI) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 15.73%.

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+15.73%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast GLSI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GLSI is 45.00 USD with a low forecast of 45.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 11.480

Low

45.00

Averages

45.00

High

45.00

Current: 11.480

Low

45.00

Averages

45.00

High

45.00

Noble Capital

Outperform

initiated

$45

2025-08-20

Reason

Noble Capital

Price Target

$45

2025-08-20

initiated

Outperform

Reason

Noble Capital initiated coverage of Greenwich LifeSciences with an Outperform rating and $45 price target. Greenwich is developing GSLI-100, which has completed four clinical trials that lead to the design of the current Phase 3 Flamingo-01 trial for prevention of breast cancer recurrence in high-risk patients, the analyst tells investors. The firm, which estimates market entry by FY28, sees \"large market potential\" for GLSI-100.

HC Wainwright & Co.

Yi Chen

Strong Buy

Maintains

$38 → $39

2025-04-21

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$38 → $39

2025-04-21

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Yi Chen

Strong Buy

Reiterates

$38

2025-02-11

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$38

2025-02-11

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Greenwich Lifesciences Inc (GLSI.O) is -8.13, compared to its 5-year average forward P/E of -29.98. For a more detailed relative valuation and DCF analysis to assess Greenwich Lifesciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-29.98

Current PE

-8.13

Overvalued PE

3.69

Undervalued PE

-63.65

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00